Your browser doesn't support javascript.
loading
ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts.
Ollivier-Hourmand, Isabelle; Repesse, Yohann; Nahon, Pierre; Chaffaut, Cendrine; Dao, Thông; Nguyen, Thi Thu Nga; Marcellin, Patrick; Roulot, Dominique; De Ledinghen, Victor; Pol, Stanislas; Guyader, Dominique; Archambeaud, Isabelle; Zoulim, Fabien; Oberti, Frédéric; Tran, Albert; Bronowicki, Jean-Pierre; D'Alteroche, Louis; Ouzan, Denis; Peron, Jean-Marie; Zarski, Jean-Pierre; Bourliere, Marc; Larrey, Dominique; Louvet, Alexandre; Cales, Paul; Abergel, Armand; Mathurin, Philippe; Mallat, Ariane; Blanc, Jean-Frederic; Nguyen-Khac, Eric; Riachi, Ghassan; Alric, Laurent; Serfaty, Lawrence; Antonini, Teresa; Moreno, Christophe; Attali, Pierre; Thabut, Dominique; Pilette, Christophe; Grange, Jean-Didier; Silvain, Christine; Carbonell, Nicolas; Bernard-Chabert, Brigitte; Goria, Odile; Wartelle, Claire; Moirand, Romain; Christidis, Christos; Perlemuter, Gabriel; Ozenne, Violaine; Henrion, Jean; Hillaire, Sophie; Di Martino, Vincent.
Affiliation
  • Ollivier-Hourmand I; Department of Hepatogastroenterology, University Hospital, Caen, France.
  • Repesse Y; Hematology Laboratory, University Hospital, Caen, France.
  • Nahon P; AP-HP, Hôpital Avicenne, Bobigny, France.
  • Chaffaut C; University Sorbonne Paris Nord, Bobigny, France.
  • Dao T; Inserm, UMR-1138 « Functional Genomics of Solid Tumors ¼, Centre de Recherche des Cordeliers, Université de Paris, Paris, France.
  • Nguyen TTN; SBIM, APHP, Hôpital Saint-Louis, Inserm, UMR-1153, ECSTRA Team, Paris, France.
  • Marcellin P; Department of Hepatogastroenterology, University Hospital, Caen, France.
  • Roulot D; Department of Hepatogastroenterology, University Hospital, Caen, France.
  • De Ledinghen V; AP-HP, Hôpital Beaujon, Service d'Hepatologie, Clichy, France.
  • Pol S; AP-HP, Hôpital Avicenne, Bobigny, France.
  • Guyader D; University Sorbonne Paris Nord, Bobigny, France.
  • Archambeaud I; Hepatology Unit, University Hospital Haut Levêque, CHU Bordeaux, Pessac, France.
  • Zoulim F; AP- HP, Hôpital Cochin, Departement d'Hepatologie et INSERM U1016, Université Paris Descartes, Paris, France.
  • Oberti F; CHU Pontchaillou, Service d'Hepatologie, Rennes, France.
  • Tran A; Liver Unit, CHU, Nantes, France.
  • Bronowicki JP; Hôpital Hôtel Dieu, Service d'Hepatologie, Lyon, France.
  • D'Alteroche L; Liver Unit, University Hospital, Angers, France.
  • Ouzan D; CHU de Nice, Service d'Hepatologie, et INSERM U1065, Universite de Nice-Sophia-Antipolis, Nice, France.
  • Peron JM; Hôpital Brabois, Service d'Hepatologie, Vandoeuvre-les-Nancy, Nancy, France.
  • Zarski JP; Liver Unit, University Hospital Trousseau, Tours, France.
  • Bourliere M; Institut Arnaud Tzanck, Service d'Hepatologie, St Laurent du Var, France.
  • Larrey D; Liver Unit, Universitary Hospital Purpan, University Paul Sabatier III, Toulouse, France.
  • Louvet A; Hôpital Michallon, Service d'Hepatologie, Grenoble, France.
  • Cales P; Hôpital Saint Joseph, Service d'Hepatologie, Marseille, France.
  • Abergel A; Hôpital Saint Eloi, Service d'Hepatologie, Montpellier, France.
  • Mathurin P; Liver Unit, University Hospital, Lille, France.
  • Mallat A; Liver Unit, University Hospital, Angers, France.
  • Blanc JF; Hôpital Hôtel Dieu, Service d'Hepatologie, Clermont-Ferrand, France.
  • Nguyen-Khac E; Liver Unit, University Hospital, Lille, France.
  • Riachi G; AP-HP, Hôpital Henri Mondor, Service d'Hepatologie, Creteil, France.
  • Alric L; Hôpital St Andre, Service d'Hepatologie, Bordeaux, France.
  • Serfaty L; Liver Unit, University Hospital, Amiens, France.
  • Antonini T; Liver Unit, University Hospital Charles-Nicolle, Rouen, France.
  • Moreno C; CHU Toulouse, Service de Medecine Interne-Pôle Digestif UMR 152, Toulouse, France.
  • Attali P; AP-HP, Hôpital Saint-Antoine, Service d'Hepatologie, Paris, France.
  • Thabut D; Liver Unit, APHP, CHU Paul Brousse, Villejuif, France.
  • Pilette C; Liver Unit, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Grange JD; AP-HP, CHU Kremlin-Bicêtre, Service d'Hepatologie, Le Kremlin-Bicêtre, France.
  • Silvain C; AP-HP, Hôpital La Pitié Salpétrière, Service d'Hepatologie, Paris, France.
  • Carbonell N; CHU Le Mans, Service d'Hepatologie, Le Mans, France.
  • Bernard-Chabert B; AP-HP, Hôpital Tenon, Service d'Hepatologie, Paris, France.
  • Goria O; CHU de Poitiers, Service d'Hepatologie, Poitiers, France.
  • Wartelle C; AP-HP, Hôpital Saint-Antoine, Service d'Hepatologie, Paris, France.
  • Moirand R; Hôpital Robert Debré, Service d'Hepatologie, Reims, France.
  • Christidis C; Liver Unit, University Hospital Charles-Nicolle, Rouen, France.
  • Perlemuter G; Hôpital d'Aix-En-Provence, Service d'Hepatologie, Aix-En-Provence, France.
  • Ozenne V; University of Rennes, INSERM, INRA, CHU Rennes, Institut NUMECAN (Nutrition Metabolisms and Cancer), Rennes, France.
  • Henrion J; Institut Mutualiste Montsouris, Service d'Hepatologie, Paris, France.
  • Hillaire S; Liver Unit, University Hospital, Béclère, APHP, Clamart, France.
  • Di Martino V; Liver Unit, APHP, CHU Lariboisière, Paris, France.
Liver Int ; 42(6): 1386-1400, 2022 06.
Article in En | MEDLINE | ID: mdl-35025128
ABSTRACT
BACKGROUND AND

AIMS:

Non-O blood group promotes deep vein thrombosis and liver fibrosis in both general population and hepatitis C. We aimed to evaluate the influence of Non-O group on the outcome of Child-Pugh A cirrhotic patients.

METHODS:

We used two prospective cohorts of Child-Pugh A cirrhosis due to either alcohol or viral hepatitis. Primary end point was the cumulated incidence of 'Decompensation' at 3 years, defined as the occurrence of ascites , hydrothorax, encephalopathy, gastrointestinal bleeding related to portal hypertension, or bilirubin >45 µmol/L. Secondary end points were the cumulated incidences of (1) 'Disease Progression' including a « decompensation¼ or « the occurrence of one or more parameters ¼ among prothrombin time (PT) <45%, albumin <28 g/L, Child-Pugh worsening (B or C vs A or B, C vs B), hepatorenal syndrome, and hepato-pulmonary syndrome, (2) other events such as non-malignant portal vein thrombosis (nmPVT), and (3) overall survival.

RESULTS:

Patients (n = 1789; 59.9% Non-O group; 40.1% group O) were followed during a median of 65.4 months. At 3 years cumulated incidence of Decompensation was 8.3% in Non-O group and 7.2% in group O (P = .27). Cumulated incidence of Disease Progression was 20.7% in Non-O group and 18.9% in group O (P = .26). Cumulated incidence of nmPVT was 2.7% in Non-O group and 2.8% in group O (P = .05). At 3 years overall survival was 92.4% in Non-O group and 93.4% in group O (P = 1).

CONCLUSION:

Non-O group does not influence disease outcome in Child-Pugh A cirrhotic patients. Clinicals trial number NCT03342170.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: ABO Blood-Group System / Hypertension, Portal Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Liver Int Journal subject: GASTROENTEROLOGIA Year: 2022 Type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: ABO Blood-Group System / Hypertension, Portal Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Liver Int Journal subject: GASTROENTEROLOGIA Year: 2022 Type: Article Affiliation country: France